{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:15:07Z","timestamp":1783782907956,"version":"3.55.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Atrial fibrillation (AF) is frequent in dialysis patients and associates with a substantial increase in stroke, cardiovascular events, and mortality, yet the net clinical benefit of oral anticoagulation (OAC) in this setting remains uncertain. Dialysis patients were excluded from pivotal vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) trials, and observational data are conflicting. The PRO position argues that in carefully selected patients with very high thromboembolic risk and acceptable bleeding risk, thromboembolic prophylaxis\u2014pharmacological with OAC or non-pharmacological with left atrial appendage closure (LAAC)\u2014can reduce stroke and possibly mortality. This view is supported by several cohort studies suggesting lower ischemic events and improved survival when OAC is maintained, and international normalized ratio control is good, and by emerging data that LAAC may offer similar stroke protection with less bleeding and lower mortality than OAC or no prophylaxis. The CON position stresses that many large studies show no clear stroke reduction and consistently higher major bleeding with warfarin versus no OAC, that small randomized controlled trials of DOACs versus VKAs reveal very high absolute bleeding without clear efficacy gains, and that VKAs may aggravate vascular calcification. Both positions agree on the need for individualized, shared decision-making and for adequately powered randomized trials comparing OAC and LAAC with no specific therapy in dialysis AF.<\/jats:p>","DOI":"10.1093\/ckj\/sfag217","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:51:19Z","timestamp":1782388279000},"source":"Crossref","is-referenced-by-count":0,"title":["Oral anticoagulation and left atrial appendage closure in dialysis atrial fibrillation: between stroke prevention and bleeding hazard"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4699-4149","authenticated-orcid":false,"given":"Simonetta","family":"Genovesi","sequence":"first","affiliation":[{"name":"Istituto Auxologico Italiano, IRCCS , Milan ,","place":["Italy"]},{"name":"School of Medicine and Surgery, University of Milano-Bicocca , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2487-8366","authenticated-orcid":false,"given":"Toshiki","family":"Kuno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Immunology, RWTH Aachen University Hospital , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-1996","authenticated-orcid":false,"given":"Carmine","family":"Zoccali","sequence":"additional","affiliation":[{"name":"Associazione Ipertensione, Nefrologia, Trapianto Renale (IPNET) , Reggio Cal ,","place":["Italy"]},{"name":"Institute of Biology and Molecular Genetics , Ariano Irpino ,","place":["Italy"]},{"name":"Renal Research Institute , NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"2026071111011920500_bib1","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van\u00a0Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026071111011920500_bib2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the diagnosis and management of atrial fibrillation","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"2026071111011920500_bib3","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1093\/ndt\/gfs416","article-title":"Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis","volume":"27","author":"Zimmerman","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026071111011920500_bib4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.ajkd.2007.10.034","article-title":"Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients","volume":"51","author":"Genovesi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2026071111011920500_bib5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10157-020-01991-9","article-title":"Impact of atrial fibrillation on the risk of ischemic stroke in patients on hemodialysis: BOREAS-HD3 study","volume":"25","author":"Kimura","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2026071111011920500_bib6","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1016\/j.ekir.2024.06.027","article-title":"Major bleeding rates in an international cohort of patients with end-stage kidney disease","volume":"9","author":"Coyle","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026071111011920500_bib7","doi-asserted-by":"publisher","first-page":"e70120","DOI":"10.1111\/eci.70120","article-title":"Oral anticoagulant therapy for patients with atrial fibrillation on long-term dialysis: a network meta-analysis of 137,574 patients","volume":"55","author":"Du","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"2026071111011920500_bib8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"2026071111011920500_bib9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2015.05.019","article-title":"Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation","volume":"66","author":"Shen","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026071111011920500_bib10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40620-016-0364-8","article-title":"Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study","volume":"30","author":"Genovesi","year":"2017","journal-title":"J Nephrol"},{"key":"2026071111011920500_bib11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.hrthm.2017.01.047","article-title":"Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation","volume":"14","author":"Kai","year":"2017","journal-title":"Heart Rhythm"},{"key":"2026071111011920500_bib12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.ajkd.2025.10.009","article-title":"Effectiveness and safety of apixaban initiation following newly diagnosed atrial fibrillation in patients with kidney failure on hemodialysis","volume":"87","author":"Winkelmayer","year":"2026","journal-title":"Am J Kidney Dis"},{"key":"2026071111011920500_bib13","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.113.004777","article-title":"Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis","volume":"129","author":"Shah","year":"2014","journal-title":"Circulation"},{"key":"2026071111011920500_bib14","doi-asserted-by":"publisher","first-page":"sfae029","DOI":"10.1093\/ckj\/sfae029","article-title":"Anticoagulation in patients with end-stage kidney disease and atrial fibrillation: a national population-based study","volume":"17","author":"Kim","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026071111011920500_bib15","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s40620-025-02340-3","article-title":"Efficacy and safety of antithrombotics in patients with atrial fibrillation undergoing hemodialysis: a nationwide cohort study in Korea","volume":"38","author":"Park","year":"2025","journal-title":"J Nephrol"},{"key":"2026071111011920500_bib16","first-page":"487","article-title":"Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in hemodialysis patients with atrial fibrillation","volume":"19","author":"Rebora","year":"2021","journal-title":"Blood Transfus"},{"key":"2026071111011920500_bib17","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026071111011920500_bib18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.31083\/j.rcm2509321","article-title":"Safety and effectiveness outcomes between apixaban versus vitamin k antagonists in atrial fibrillation patients on dialysis","volume":"25","author":"Guo","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"2026071111011920500_bib19","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"2026071111011920500_bib20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jacc.2019.10.059","article-title":"Oral anticoagulation for patients with atrial fibrillation on long-term dialysis","volume":"75","author":"Kuno","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026071111011920500_bib21","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"2026071111011920500_bib22","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1093\/ckj\/sfad221","article-title":"Long-term safety and efficacy of left atrial appendage occlusion in dialysis patients with atrial fibrillation: a multi-center, prospective, open-label, observational study","volume":"16","author":"Genovesi","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026071111011920500_bib23","doi-asserted-by":"publisher","first-page":"e1086","DOI":"10.1016\/j.hrthm.2025.07.051","article-title":"Left atrial appendage closure vs oral anticoagulation for stroke prevention in atrial fibrillation: long-term outcomes from 4 randomized trials","volume":"22","author":"Kaisaier","year":"2025","journal-title":"Heart Rhythm"},{"key":"2026071111011920500_bib24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.carrev.2024.08.016","article-title":"Adverse outcomes with left atrial appendage occlusion device implantation in chronic and end stage kidney disease: a systematic review and meta-analysis","volume":"75","author":"Gill","year":"2025","journal-title":"Cardiovasc Revasc Med"},{"key":"2026071111011920500_bib25","doi-asserted-by":"publisher","first-page":"e2530990","DOI":"10.1001\/jamanetworkopen.2025.30990","article-title":"Left atrial appendage occlusion vs anticoagulants in dialysis with atrial fibrillation","volume":"8","author":"Dhar","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026071111011920500_bib26","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.3390\/jcm15072641","article-title":"Systematic review and meta-analysis of the frequency of thromboembolic events, bleeding, and mortality in patients with atrial fibrillation and end-stage renal disease undergoing percutaneous left atrial appendage closure","volume":"15","author":"Martinez-Arango","year":"2026","journal-title":"J Clin Med"},{"key":"2026071111011920500_bib27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/pace.15208","article-title":"Optimal thromboembolism prevention for patients with atrial fibrillation on long-term dialysis","volume":"48","author":"Hashimoto","year":"2025","journal-title":"Pacing Clin Electrophis"},{"key":"2026071111011920500_bib28","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1016\/j.jcin.2025.07.038","article-title":"Outcomes of stroke prevention strategies in patients with atrial fibrillation and end-stage renal disease","volume":"18","author":"Al-Abcha","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"key":"2026071111011920500_bib29","doi-asserted-by":"publisher","first-page":"101200","DOI":"10.1016\/j.xkme.2025.101200","article-title":"Systematic review and meta-analysis of the predictive performance of stroke and bleeding prediction models in atrial fibrillation patients with kidney disease","volume":"8","author":"Langenhuijsen","year":"2025","journal-title":"Kidney Med"},{"key":"2026071111011920500_bib30","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/ndt\/gfae121","article-title":"Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation","volume":"39","author":"Genovesi","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026071111011920500_bib31","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"key":"2026071111011920500_bib32","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"2026071111011920500_bib33","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De\u00a0Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026071111011920500_bib34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ki.2009.126","article-title":"Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification?","volume":"76","author":"Krueger","year":"2009","journal-title":"Kidney Int"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag217\/68627882\/sfag217.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/7\/sfag217\/68627882\/sfag217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/7\/sfag217\/68627882\/sfag217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:01:22Z","timestamp":1783782082000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag217\/8719018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag217","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,26]]},"article-number":"sfag217"}}